The reasons for the shortage of new drugs coming through the pipeline are the subject of much debate, and the pipeline for diagnostics is one factor that will become increasing relevant to this problem as the co-development of drugs and diagnostics becomes more common. Phillips and colleagues examine the characteristics of the pipeline for diagnostics and biomarkers, and consider what steps could be taken to solve the problems identified.
- Kathryn A. Phillips
- Stephanie Van Bebber
- Amalia M. Issa